About the Company
Athersys is a clinical-stage biotechnology company developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Our focus is on the treatment of medical conditions where there is significant unmet clinical need.
We are developing MultiStem®, a patented, adult-derived “off-the-shelf” stem cell product platform, for multiple disease indications in the areas of inflammatory and immune, neurological, and cardiovascular disease. We have two ongoing clinical studies – a Phase 2 study in ulcerative colitis being conducted with Pfizer and a Phase 2 study in ischemic stroke – and overall five clinical stage programs in inflammatory bowel disease, stroke, graft-versus-host disease, acute myocardial infarction and solid organ transplant.
Athersys has forged a network of strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research and clinical institutions, in the United States and Europe to further develop its platform and products.
CLEVELAND, Nov. 09, 2016 (GLOBE NEWSWIRE) — Athersys, Inc. (ATHX) today announced its financial results for the three months ended September 30, 2016. Highlights of the third quarter of 2016 and recent events include: Announced agreement with U.S. Food...
CLEVELAND, Nov. 03, 2016 (GLOBE NEWSWIRE) — Athersys, Inc. (ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present at the Stifel 2016 Healthcare Conference at the Lotte New York Palace Hotel in New York. The presentation...
CLEVELAND, Oct. 11, 2016 (GLOBE NEWSWIRE) — Athersys, Inc. (ATHX) will release its third quarter 2016 financial results at approximately 4:00 PM Eastern Time on Wednesday, November 9, 2016, and host a conference call shortly thereafter at 4:30 PM...
Athersys Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Study of MultiStem® Treatment for Ischemic Stroke
CLEVELAND, Sept. 28, 2016 (GLOBE NEWSWIRE) — Athersys, Inc. (ATHX) announced today that it has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the design and planned analysis of a...